Skip to content

Preferred Stock at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$0
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
LQD
Liquidia CorporationLQDA
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s preferred stock?
Mirum Pharmaceuticals, Inc. (MIRM) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.